<DOC>
	<DOCNO>NCT00927797</DOCNO>
	<brief_summary>The combination Fludarabine Cyclophosphamide yield overall response rate 80 % previously untreated patient indolent Non-Hodgkin-Lymphoma . However , hematotoxicity rate high Grade 3 4 toxicity 50 % . Several study indicate treatment Pentostatin Cyclophosphamide cause low hematotoxicity rate combination Fludarabine Cyclophosphamide . To evaluate efficacy safety treatment Pentostatin/Cyclophosphamide immuno-chemotherapy patient newly diagnose relapse Immunocytoma/Morbus Waldenström , B-cell chronic lymphocytic leukemia ( B-CLL ) indolent CD20-positive B-NHL , open , non-randomized , multi-center prospective phase II-study evaluate efficacy safety treatment immuno-chemotherapy conduct . Treatment consist 6 course Pentostatin ( 4mg/m² day 1 ) , Cyclophosphamide ( 600mg/m² day 1 ) Rituximab ( 375mg/m² day 0 ) administer every three week . Patients achieve complete partial remission undergo maintenance therapy consist 8 course Rituximab ( 375mg/m² ) administer every three month period 2 year .</brief_summary>
	<brief_title>Interventional Study Pentostatin , Cyclophosphamide Rituximab Indolent B-Cell Non-Hodgkin-Lymphoma ( B-NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>confirm first diagnosis relapse CD20positive Immunocytoma , BCLL indolent BNHL therapyrequiring CLL define : Binet stage C Binet B combine occurence Bsymptoms , rapidly progress disease , risk organ compression lymphoma mass therapyrequiring Immunocytoma define Consensus Panel Recommendations Second International Workshop Waldenström´s Macroglobulinemia , 2003 ) age &gt; 18 year anticipated life expectancy &gt; 6 month ECOG 03 significant comorbidities sign informed consent efficient method contraception time therapy ( men woman ) age &lt; 18 year CD20 negativity significant comorbidities interfere therapy require protocol history HIV infection active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>immunochemotherapy</keyword>
	<keyword>Pentostatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Maintenance</keyword>
	<keyword>indolent B-NHL</keyword>
	<keyword>B-CLL</keyword>
	<keyword>B-NHL</keyword>
</DOC>